The next advance in
enterprise-scale, generative AI
for Biopharma is here.
Empowering discovery, clinical and commercial teams with unprecedented, actionable knowledge.
In real time.
A revolutionary solution
Synthetica Bio’s trailblazing solution is defining an entirely new category in the field of enterprise-scale, generative-AI for biopharma. And we are the very first venture-backed company to do so.
By leveraging the transformative power of AI, we have revolutionized how diverse, large language model (LLM) technology is utilized in real-time for biopharma discovery, clinical, and commercial teams.
The result? A platform that enables individuals in the pharmaceutical industry, regardless of their level of analytics expertise, to effortlessly and accurately inquire about complex data.
GenAI-based Architecture
Fine-tuned LLMs designed for real-time data with verified and secure customer data store
Inception Training Set
Over 220 million patient records in our datalake – and growing: fine tuned LLMs with continuous learning
Real Time Data Processing
We are currently processing over half a billion patient test results per month and growing.
Our founders
Simon Arkell
Simon is a hi tech entrepreneur and investor with a focus on AI and healthcare technology. Co-founder of 7 venture backed companies, including Deep Lens, Predixion Software and Versifi, which together raised over $100M in venture backing. All three were acquired.
AI/Health-Tech Founder | Investor | Board Member | 2X Olympian
Alex Dickinson
Co-founder/Chair/CEO: ChromaCode (COVID XPrize winner); Helixis (acquired by Illumina) and Luxtera (acquired by Cisco). Board member Gencove (low pass sequencing) and previously PRA Health Sciences (public, acquired by ICON). Seven year Illumina SVP (led BaseSpace and PopSeq businesses). Began career in research at Bell Labs; co-inventor of the CMOS fingerprint sensor.